Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles.
Commercial seasonal flu vaccines induce production of antibodies directed mostly towards hemaglutinin (HA). Because HA changes rapidly in the circulating virus, the protection remains partial. Several conserved viral proteins, e.g., nucleocapsid (NP) and matrix proteins (M1), are present in the vacc...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3126827?pdf=render |
id |
doaj-f155b5dfb5524ca0af12f56e32e8111e |
---|---|
record_format |
Article |
spelling |
doaj-f155b5dfb5524ca0af12f56e32e8111e2020-11-24T21:50:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0166e2152210.1371/journal.pone.0021522Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles.Christian SavardAnnie GuérinKarine DrouinMarilène BolducMarie-Eve Laliberté-GagnéMarie-Christine DumasNathalie MajeauDenis LeclercCommercial seasonal flu vaccines induce production of antibodies directed mostly towards hemaglutinin (HA). Because HA changes rapidly in the circulating virus, the protection remains partial. Several conserved viral proteins, e.g., nucleocapsid (NP) and matrix proteins (M1), are present in the vaccine, but are not immunogenic. To improve the protection provided by these vaccines, we used nanoparticles made of the coat protein of a plant virus (papaya mosaic virus; PapMV) as an adjuvant. Immunization of mice and ferrets with the adjuvanted formulation increased the magnitude and breadth of the humoral response to NP and to highly conserved regions of HA. They also triggered a cellular mediated immune response to NP and M1, and long-lasting protection in animals challenged with a heterosubtypic influenza strain (WSN/33). Thus, seasonal flu vaccine adjuvanted with PapMV nanoparticles can induce universal protection to influenza, which is a major advancement when facing a pandemic.http://europepmc.org/articles/PMC3126827?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christian Savard Annie Guérin Karine Drouin Marilène Bolduc Marie-Eve Laliberté-Gagné Marie-Christine Dumas Nathalie Majeau Denis Leclerc |
spellingShingle |
Christian Savard Annie Guérin Karine Drouin Marilène Bolduc Marie-Eve Laliberté-Gagné Marie-Christine Dumas Nathalie Majeau Denis Leclerc Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. PLoS ONE |
author_facet |
Christian Savard Annie Guérin Karine Drouin Marilène Bolduc Marie-Eve Laliberté-Gagné Marie-Christine Dumas Nathalie Majeau Denis Leclerc |
author_sort |
Christian Savard |
title |
Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. |
title_short |
Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. |
title_full |
Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. |
title_fullStr |
Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. |
title_full_unstemmed |
Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. |
title_sort |
improvement of the trivalent inactivated flu vaccine using papmv nanoparticles. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2011-01-01 |
description |
Commercial seasonal flu vaccines induce production of antibodies directed mostly towards hemaglutinin (HA). Because HA changes rapidly in the circulating virus, the protection remains partial. Several conserved viral proteins, e.g., nucleocapsid (NP) and matrix proteins (M1), are present in the vaccine, but are not immunogenic. To improve the protection provided by these vaccines, we used nanoparticles made of the coat protein of a plant virus (papaya mosaic virus; PapMV) as an adjuvant. Immunization of mice and ferrets with the adjuvanted formulation increased the magnitude and breadth of the humoral response to NP and to highly conserved regions of HA. They also triggered a cellular mediated immune response to NP and M1, and long-lasting protection in animals challenged with a heterosubtypic influenza strain (WSN/33). Thus, seasonal flu vaccine adjuvanted with PapMV nanoparticles can induce universal protection to influenza, which is a major advancement when facing a pandemic. |
url |
http://europepmc.org/articles/PMC3126827?pdf=render |
work_keys_str_mv |
AT christiansavard improvementofthetrivalentinactivatedfluvaccineusingpapmvnanoparticles AT annieguerin improvementofthetrivalentinactivatedfluvaccineusingpapmvnanoparticles AT karinedrouin improvementofthetrivalentinactivatedfluvaccineusingpapmvnanoparticles AT marilenebolduc improvementofthetrivalentinactivatedfluvaccineusingpapmvnanoparticles AT marieevelalibertegagne improvementofthetrivalentinactivatedfluvaccineusingpapmvnanoparticles AT mariechristinedumas improvementofthetrivalentinactivatedfluvaccineusingpapmvnanoparticles AT nathaliemajeau improvementofthetrivalentinactivatedfluvaccineusingpapmvnanoparticles AT denisleclerc improvementofthetrivalentinactivatedfluvaccineusingpapmvnanoparticles |
_version_ |
1725883191265329152 |